TAT-11: U.S. DOE Tri-Lab Research and Production Effort to Provide Accelerator-Produced Ac-225 for Radiotherapy: 2019 Update

Ottawa, ON, Canada (UroToday.com) Dr, John presented an update on the isotope production activities with the Tri-Lab Consortium (BNL, LANL, and ORNL) within the Department of Energy. Previously most of the Ac225 came from a Th229/Ac225 generator. Currently, accelerators at both LANL and BNL are producing Ac225 by proton bombardment of Thorium via the Th232[p,x]Ac225 spallation reaction.

Techniques for preparing and handling the Thorium targets and extraction of the Ac225 have been worked out. LANL has been producing 1.3-2 mCi10-hour hour exposure. They have already distributed 250 mCi to researchers. Stage 2 plans to increase this to 50-100 mCi. Looking forward to the day when clinical quantities of Ac225 may be required, they are working with companies and hospitals and are developing an FDA Drug Master File (DMF) for support in Phase I trials.


Presented by: Kevin John, PhD, Science Program Officer, Los Alamos National Laboratory, Los Alamos, New Mexico, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe